BCG

Intercept Pharmaceuticals is a biopharmaceutical company based in New York, NY, dedicated to developing innovative medicines for individuals living with rare and serious liver diseases. With a focus on advancing treatments for conditions such as Primary Biliary Cholangitis (PBC), the company aims to improve patient outcomes through novel scientific discoveries and a commitment to addressing high unmet medical needs. Founded in 2002, Intercept has built a robust pipeline of investigational therapies and continues to pioneer solutions in liver health. The company fosters a collaborative and passionate work environment, driven by a mission to make a meaningful impact on the lives of patients affected by liver diseases. Generated from the website

Every day, Guardian makes the lives of 27 million Americans more secure through our insurance and wealth management products and services. From our founding in 1860, doing the right thing for our policyholders and customers has guided everything we do...